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Background: Due to recent advances in treatment, nearly 80% of childhood cancer patients become long-term
survivors. Studies on the late effects of survivors are under way worldwide. However, data on Asian survivors remain
limited.
Methods: Data on 241 survivors at the Long-term Follow-up Clinic in Severance Hospital, South Korea, were
collected and late effects were confirmed by oncologists.
Results: The median follow-up from diagnosis was 7.8 years. Late effects were identified in 59.8% of survivors and
23.2% had two or more late effects. Grade 3 or higher late effects were present in 10.8%. The most common late
effects involved endocrine system (29.0%). Late effects were present in 95.7% of brain tumor survivors and 36.0% of
Wilms’ tumor survivors. Chemotherapy, hematopoietic stem-cell transplantation and radiotherapy were significant
factors associated with the number and severity of late effects (P < 0.05). Brain tumor survivors had more severe late
effects (P < 0.001), whereas Wilms’ tumor survivors had fewer and milder late effects (P < 0.05).
Conclusion: The observation that over 50% of cancer survivors suffered from late effects during the short follow-up
period and that a high frequency of endocrine late effects was present indicates the need for early and well-timed
intervention of the survivors.
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introduction
Recent advances in diagnosis, treatment and supportive care
have greatly increased the childhood cancer survival rate to up
to 80% [1]. As more survivors reach adulthood, chronic toxic
effects in the survivors, the so-called ‘late effects’, are increasing
in frequency [2, 3]. In the United States, 1 of every 640 adults
between the ages of 20 and 39 years is a childhood cancer
survivor, and two of three of the survivors have at least one late
effect [4].
The range of late effects is quite broad; growth, endocrine,
cardiovascular, pulmonary, kidney and neurocognitive
abnormalities have been reported [5, 6]. Due to increasing
concern about the chronic health conditions and health status
including quality of life (QoL) of survivors, many guidelines for
long-term follow-up have been developed [7]. Many health
professionals, including general physicians, oncologists, nurse
practitioners and social workers, are working together to
improve the health and QoL of the survivors [8, 9].
There are many published reports on late effects and health
status, which includes general, mental and functional status
[4, 10–13]. As for chronic adverse health conditions or late
effects, most of the studies are on the single late effect of
childhood cancer survivors and only a few reports are on
their overall status of late effects. Furthermore, most prior
reports investigated late effects in Caucasian populations.
The purpose of this study was to assess the overall status
of late effects of Asian childhood cancer survivors.
methods
patient selection
In January 2005, the Long-term Follow-up Clinic (LTFUC) for childhood
cancer survivors was established at Severance Hospital, Yonsei University
Health System (YUHS), Seoul, Korea. A childhood cancer survivor was
defined as a person who survived for at least 2 years off of cancer therapy.
There is a society of childhood cancer survivors at Severance Hospital
comprising over 700 members including 408 survivors. We invited the
survivors registered in this society by mail to come to the LTFUC. All
patients were diagnosed at <18 years of age and were treated from 1980 to
2007 at Severance Hospital. Three hundred and fifty members visited the
LTFUC from January 2005 to October 2007. We excluded the following
members: those with a time after completion of treatment of <2 years
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(48 cases) and patients with incomplete data (61 cases). Finally, data from
241 survivors were analyzed. Remaining 167 survivors in the society were
regarded as the nonrespondents.
data collection
The treatment history and health risks of each survivor were reviewed
through medical records. Patient-individualized follow-up schedules, based
on individual risks, were prepared for each survivor. The follow-up protocol
at YUHS was adopted and modified from the Long-term Follow-up
Guidelines of the Children’s Oncology Group, the national clinical guideline
for long-term follow-up of childhood cancer survivors developed by the
Scottish Intercollegiate Guidelines Network and the Practice Statement of the
UK Children’s Cancer Study Group, taking the cost, effectiveness and
regional environments of Korea into consideration [14–16].
The LTFUC focused on three primary areas: late effects, follow-up of
disease status and psychological assessment. For the follow-up of disease
status, disease relapse was assessed; patients with disease relapse were
referred to the hematology–oncology clinic (HOC). For assessment of late
effects, a complete history and physical examination was carried out for
each survivor. Laboratory and radiological tests were carried out based on
the follow-up schedule. All survivors who visited the LTFUC at least once
were followed regularly.
data analysis
Late effects were defined as the adverse events that the survivors had at least
2 years after completion of therapy (Table 1). Specific late effects evaluated
in the LTFUC were selected referring to the late effects stated in the
aforementioned protocols [14–16]. The severity of specific late effect was
graded by the Common Terminology Criteria for Adverse Events version
3.0 in the same way as in previous reports [4, 11]. The late effects were
scored from grades 1 to 5 with descriptions of severity for each adverse
event (grade 1, mild; 2, moderate; 3, severe; 4, life threatening or disabling;
5, death-related adverse event). To compare the severity between risk
groups and utilize the ordered meaning of grades, the grade was considered
as a continuous variable from 1 to 5, based on other reports [17, 18].
In addition, the late effects were classified by organs and systems to avoid
overlapping counts of late effects; the number of late effects represents the
number of affected body systems (Table 1). The mean number of late effects
per survivor, with specific risk factors, was calculated. The existence of late
effects refers to whether a late effect existed or not.
statistical analyses
The significance of various risk factors for the existence was tested by chi-
square test, and the significance for number and severity of late effects was
tested by Student’s t-test, one-way analysis of variance and correlation
analysis using Pearson’s coefficient. The difference between two groups for
nonparametric variables was tested by Mann–Whitney test.
The risk factors that were significant in the univariate analyses were
considered as the variables for multivariate analysis. Multiple linear
regression for the association between risk factors and the number or
severity of late effects and logistic regression to assess the odds ratio (OR)
for the existence of late effects were carried out. Analyses were carried out
using SPSS version 11.5.0 (SPSS System Inc., Chicago, IL).
results
survivor characteristics
Among the members in the society, 408 were survivors and 241
had responded (Table 2, supplemental Table S1, available at
Annals of Oncology online). One hundred and fifty survivors
were male (62.2%) and 91 were female (37.8%). The median
age at diagnosis was 4.4 (0–16.8) years and the median current
age was 14.2 (2.6–33.7) years. The median time elapsed after
completion of treatment was 6.1 (2.0–21.6) years and the
median time after diagnosis was 7.8 (2.0–23.1) years.
Table 1. Categorization of specific late effects
Involved system Specific late effectsa
Bone marrow Anemia, polycythemia, leukopenia, marrow
hypocellularity, neutropenia,
thrombocytopenia, thrombocytosis, other
Skin Alopecia, atrophy, fibrosis, nail changes,
vitiligo, other
Obesity Obesity (based on BMI), other
Ear Hearing loss, otitis externa, otitis media,
tinnitus, other
Eye Cataract, dry eye syndrome, glaucoma,
retinopathy, uveitis, vitreous
hemorrhage, other
Cardiovascular Cardiac arrhythmia, cardiomyopathy,
congestive heart failure, hypertension,
hypotension, ventricular dysfunction, other
Lung Paranasal sinus infection, pneumonitis,
pulmonary dysfunction, pulmonary
fibrosis, other
Gastrointestinal Bowel obstruction, colitis, dental abnormalities,
chronic enterocolitis, constipation, fecal
incontinence, hepatic dysfunction, ileus,
malabsorption, mucositis, other
Kidney Hematuria, hemorrhagic cystitis, incontinence,
proteinuria, renal insufficiency, renal tubular
disorder, other
Neurologic Ataxia, cerebrovascular ischemia, cognitive
disturbance, dizziness, hydrocephalus,
leukoencephalopathy, memory impairment,
mood alteration, neuropathy (cranial, motor
or sensory), phrenic nerve dysfunction,
seizures, speech impairment, tremor, other
Musculoskeletal Fracture, limb discrepancy, musculoskeletal
hypoplasia, osteonecrosis, osteopenia,
osteoporosis, scoliosis, other
Thyroid Hyperthyroidism, hypothyroidism, thyroid
nodule, other
Growth Growth deceleration, growth hormone
deficiency, short stature, other
Sexual/puberty Delayed puberty, gonadotrophin secretion
abnormality, gynecomastia, primary gonadal
failure, premature menopause, infertility,
irregular menses, precocious puberty, other
Metabolic Adrenal insufficiency, dyslipidemia, glucose
intolerance, hypocalcemia, hypercalcemia, other
aLate effects were expressed using the terminology based on the Common
Terminology Criteria for Adverse Events version 3.0. Adverse events
confirmed 2 years after completion of cancer therapy were regarded as late
effects rather than acute treatment toxic effects. Evaluation methods were
selected based on risk and individualized follow-up schedules, which were
determined according to the treatment history of the survivor. For all
categories, history and physical examination were included. Evaluations
were repeated at appropriate follow-up intervals for each late effect.
BMI, body mass index.
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Ninety-five survivors (39.4%) had leukemia and 35 (14.5%)
had lymphoma. Other diagnoses included Wilms’ tumor (25,
10.4%), brain tumors (23, 9.5%), neuroblastoma (13, 5.4%)
and others (50, 20.7%). Chemotherapy was given to 233
survivors (96.7%), radiotherapy to 93 (38.6%), surgery to 96
(39.8%) and hematopoietic stem-cell transplantation (HSCT)
to 42 (17.4%). Chemotherapy and radiotherapy were given to
92 (38.2%) survivors simultaneously. Median dosage of
anthracyclines in the group treated with anthracyclines was
167.9 (30.2–1160.0) mg/m2.
Among 167 nonrespondents, 99 (59.3%) were male and 68
(40.7%) were female. The median age at diagnosis was 4.7 (0–
17.1) years and it was not different from that of the respondents
(P = 0.751). However, the median current age, age after
completion of treatment and time after diagnosis in
nonrespondents were significantly higher than those in the
respondents (all P £ 0.001). As for the diagnosis, the
proportion of brain tumor was significantly higher in
nonrespondents than in respondents [n = 35 (21.0%) versus
n = 23 (9.5%), P < 0.001; supplemental Table S1, available at
Annals of Oncology online].
overall late effects
Among the 241 survivors, 144 (59.8%) had at least one late
effect and 97 (40.2%) had no late effects (Table 3). Two or
more late effects were present in 60 survivors (24.9%). Sixty-
one survivors (25.3%) had grade 1 (mild) late effects and 83
(34.4%) had grade 2 (moderate) or more severe late effects.
Grade 3 or more late effects were found in 10.8% of survivors.
There was no death (grade 5) in the LTFUC.
The most common late effects were endocrine related
(Table 4). Among the survivors, 70 (29.0% of 241 survivors)
had endocrine late effects including thyroid (n = 35), growth
(n = 28), sexual (n = 28), metabolic (n = 5) and other
abnormalities (n = 6). For grade 2 or higher, endocrine
abnormalities were the most common late effects that required
treatment (30, 12.4%). Among these cases, 16 had growth
abnormalities and 10 had sexual/pubertal abnormalities. For
grade 3 or higher, neurologic (n = 7) and endocrine (n = 7)
abnormalities were the most common.
Three relapses occurred: a neuroblastoma patient relapsed
2.2 years after completion of therapy, a patient with
medulloblastoma relapsed at 2.3 years and a patient with acute
lymphoblastic leukemia relapsed at 3.8 years.
Three patients who were enrolled in the LTFUC at first are
now in the HOC due to secondary malignancy: a patient
diagnosed with glioblastoma multiforme at 8.5 years of age and
then developed undifferentiated sarcoma in the bladder at 15.1
years of age, a patient with medulloblastoma at 14.2 years of
age, and then developed acute myeloid leukemia at 19.9 years
and a patient with neuroblastoma at 1.0 year of age and then
developed brain germinoma at 5.5 years of age. Patients with
second malignancies are treated and followed in the HOC and
were not included in the analysis of late effects in the 241
survivors.
late effects and treatment
number of late effects. There was no gender difference in the
number of late effects among the survivors (Table 5). Brain
Table 2. Demographic characteristics of childhood cancer survivors at
Severance Hospital
Characteristic No. of survivors (%)a
Sex
Male 150 (62.2)
Female 91 (37.8)
Age at diagnosis
(median, range)
4.4 (0–16.8) years
Current age
(median, range)
14.2 (2.6–33.7) years
Time elapsed after
diagnosis (median, range)
7.8 (2.0–23.1) years
Time elapsed after completion
of treatment (median, range)
6.1 (2.0–21.6) years
Diagnosis
Leukemia 95 (39.4)
Lymphoma 35 (14.5)
Wilms’ tumor 25 (10.4)
Brain tumor 23 (9.5)
Neuroblastoma 13 (5.4)
Othersb 50 (20.7)
Treatment modalities
Chemotherapy only with/
without surgery
141 (58.5)
Radiotherapy only with/without
surgery
1 (0.4)
Chemotherapy and radiotherapy 92 (38.2)
Surgery only 7 (2.9)
Type of chemotherapy
(n = 233, 96.7%)
Anthracyclines 124 (51.5)
Alkylating agents 152 (63.1)
Anthracyclines and
alkylating agents
103 (42.7)
Others only 60 (24.9)
Type of radiotherapy
(n = 93, 38.6%)
Head, neck and spine 65 (27.0)
Abdominopelvic 19 (7.9)
TBI 6 (2.5)
Chest 5 (2.1)
Type of surgery (n = 96, 39.8%)
Head 23 (9.5)
Abdominopelvic—kidney 27 (11.2)
Abdominopelvic—liver/adrenal
gland
13 (5.4)
Chest 7 (2.9)
Type of HSCT (n = 42, 17.4%)
Autologous 20 (8.3)
Allogeneic 22 (9.1)
aPercentage is based on total survivors (n = 241).
bOthers include 17 Langerhans cell histiocytosis (systemic type), 10
abdominopelvic germ-cell tumor, eight hepatoblastoma, five
rhabdomyosarcoma, two leiomyosarcoma, two eosinophilic granuloma,
two adrenocortical carcinoma, one Ewing sarcoma, one rhabdoid tumor of
the neck, one mediastinal teratoma, one malignant myofibroblastic tumor.
TBI, total body irradiation; HSCT, hematopoietic stem-cell transplantation.
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tumor survivors had the highest probability of having late
effects (95.7%, 22 of 23). Wilms’ tumor survivors had the
lowest risk for late effects (36.0%, 9 of 25). In terms of multiple
late effects, 52.2% of brain tumor survivors (12 of 23) had two
or more late effects. Only one Wilms’ tumor (4.0%, 1 of 25)
and two neuroblastoma survivors (15.3%, 2 of 13) had multiple
late effects. A history of a brain tumor was a significant risk
factor for an increased number of late effects (1.83 6 0.22;
P < 0.001) compared with a history of other childhood cancers.
Wilms’ tumor survivors were at lower risk for late effects
compared with other cancer survivors (0.44 6 0.14;
P < 0.001).
Chemotherapy, HSCT and radiotherapy were significant
risk factors for a high number of late effects (all P < 0.001)
when compared with survivors not treated with each of these
modalities. The age at diagnosis and the current age
correlated positively to the number of late effects (r = 0.25,
P < 0.001; r = 0.13, P = 0.049). Multivariate analysis showed
that all treatment modalities were related to an increased mean
number of late effects. Wilms’ tumor survivors had a decreased
number of late effects (Table 6).
overall grade of severity of late effects. Survivors treated with
radiotherapy had a much higher grade of late effects than
did survivors who did not receive radiotherapy (1.5 6 0.1
versus 0.8 6 0.1, P < 0.001) (Figure 1). A history
of chemotherapy or HSCT was associated with more severe
late effects when compared with the grade of late effects in
survivors who did not receive chemotherapy or HSCT
(1.1 6 0.1 versus 0.1 6 0.1, P < 0.001; 1.4 6 0.1 versus
1.0 6 0.1, P = 0.025). These findings were confirmed by
the multivariate analysis controlling for other factors such as
gender, age at diagnosis and current age (all P < 0.05,
Table 6).
Regarding diagnosis, 52.2% of all brain tumor survivors (12
of 23) had grade 3 or higher late effects, compared with only
4.2% of leukemia survivors (4 of 95). The mean grade of late
effects in brain tumor survivors was much higher than that for
survivors who did not have a brain tumor (2.3 6 0.2 versus
0.9 6 0.1, P < 0.001) (Figure 1). The severity of late effects in
Wilms’ tumor survivors was milder than in the survivors who
did not have Wilms’ tumor (0.6 6 0.2 versus 1.1 6 0.1,
P < 0.012). The effects associated with a history of brain
tumors and Wilms’ tumors were confirmed by the multivariate
analysis (Table 6). The mean age at diagnosis correlated
positively with the severity grade of late effects (r = 0.180,
P = 0.001); however, the current age and the time elapsed after
treatment did not.
relationship between severity grade of specific late effects and
treatment. Among the treatment modalities, chemotherapy was
associated with an increased growth and obesity severity grade
compared with the survivors who did not receive
chemotherapy (0.22 6 0.04 versus 0, P < 0.001; 0.27 6 0.05
versus 0, P < 0.001) (Figure 1). Radiotherapy increased the
severity of growth, thyroid and sexual late effects (0.36 6 0.08
versus 0.11 6 0.04, P = 0.006; 0.50 6 0.08 versus 0.15 6 0.05,
P = 0.001; 0.51 6 0.11 versus 0.14 6 0.06, P = 0.003).
However, all the effects associated with a history of
radiotherapy were not confirmed by the multivariate analysis
after controlling for age, gender, diagnosis and other treatment
modalities. A history of surgery increased the severity of
growth, thyroid and kidney late effects compared with the
survivors who did not have surgery by the univariate analysis
(0.42 6 0.08 versus 0.08 6 0.03, P < 0.001; 0.56 6 0.11 versus
0.24 6 0.05, P = 0.013; 0.22 6 0.07 versus 0.05 6 0.02,
P = 0.023). The effects of surgery on growth and kidney
abnormalities were confirmed by the multivariate analysis
(P < 0.05).
Table 4. Late effects by body system
System Severity of late effectsa Grade 2 or higher
severity (% in total
number of late effects)
Total
1 2 3 4
Bone marrow 5 1 0 1 2 (28.6) 7
Skin 2 3 0 0 3 (60.0) 5
Obesity 1 23 1 0 24 (96.0) 25
Ear 4 6 5 0 11 (73.3) 15
Eye 3 3 2 0 5 (62.5) 8
Cardiovascular 21 4 0 0 4 (16.0) 25
Lung 2 1 0 0 1 (33.3) 3
Gastrointestinal 8 2 1 0 3 (27.3) 11
Kidney 10 4 3 0 7 (41.2) 17
Neurologic 4 8 7 0 15 (78.9) 19
Musculoskeletal 23 3 1 0 4 (14.8) 27
Endocrinec 40 23 7 0 30 (42.9) 70
Thyroid 26 9 0 0 9 (25.7) 35
Growth 12 15 1 0 16 (57.1) 28
Sexual/puberty 18 4 6 0 10 (35.7) 28
Metabolic 5 0 0 0 0 (0) 5
Othersb 0 6 0 0 6 (100) 6
aSeverity is graded based on the Common Terminology Criteria of Adverse
Events version 3.0.
bOthers include three diabetes insipidus and three corticosteroid deficiency.
cEndocrine system includes thyroid, growth, sexual/puberty, metabolic and
other endocrine abnormalities.
Table 3. Late effects in childhood cancer survivors at Severance Hospital
Late effects No. of survivors (%)a
Existence of late effects
No 97 (40.2)
Yes 144 (59.8)
No. of late effects per survivor
1 84 (34.9)
2 37 (15.4)
3 14 (5.8)
4 8 (3.3)
5 1 (0.4)
Severity of late effects per survivorb
Mild 61 (25.3)
Moderate 57 (23.7)
Severe 25 (10.4)
Life threatening 1 (0.4)
aPercentage is based on total survivors (n = 241).
bSeverity is graded based on the Common Terminology Criteria of Adverse
Events version 3.0.
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Among the diagnoses evaluated, brain tumors were
associated with more severe endocrine late effects including
growth (1.05 6 0.23 versus 0.12 6 0.03, P = 0.001) and
thyroid abnormalities (0.95 6 0.18 versus 0.22 6 0.05,
P = 0.001) as well as severe neurological abnormalities
(2.20 6 0.39 versus 0.90 6 0.22, P = 0.004) compared with
other tumor survivors. The effects associated with a history
of brain tumors were confirmed by the multivariate analysis
(P < 0.05).
risk factors for the existence of late effects. With regards to
treatment, chemotherapy, HSCT and radiotherapy all increased
the odds for having late effects [OR 22.8, 95% confidence
interval (CI) 1.5–358.3; OR 3.9, 95% CI 1.5–9.9; OR 2.2, 95%
CI 1.1–4.5] compared with the survivors who did not undergo
each of the treatment modalities (Table 7). The diagnosis of
a brain tumor was associated with higher odds for the existence
of late effects (OR 16.6; 95% CI 1.4–192.8) compared with the
leukemia survivors. Wilms’ tumor survivors had a tendency for
lower risk of late effects than leukemia survivors (OR 0.3; 95%
CI 0.1–1.2; P = 0.097).
discussion
To recognize the prevalence and severity of late effects and to
provide timely intervention are the mainstay of health care for
the childhood cancer survivors. Our findings showed that
59.8% of survivors had late effects and 34.4% had grade 2 or
more severe late effects that required treatment. Although the
overall findings for the late effects were similar to those
previously reported, there were some differences.
According to the studies in the United States [4] and The
Netherlands [11], 62.3% and 74.5%, respectively, of childhood
cancer survivors had adverse health conditions. In the UK [19],
58% of survivors had chronic medical problems. The
prevalence of late effects in our report was slightly lower than
Table 5. Number of late effects
Risk factor No. of late effects per survivor (n, %) Survivors with
late effects (n, %)
Total survivors
(n, %)
No. of late effects
(mean, SEM)a
P value
0 1 2 3 4 5
Sex
Male 58 (38.7) 50 (33.3) 29 (19.3) 8 (5.3) 4 (2.7) 1 (0.7) 92 (61.3) 150 (100) 1.02 6 0.09 0.499
Female 39 (42.9) 34 (37.4) 8 (8.8) 6 (6.6) 4 (4.4) 0 (0) 52 (57.1) 91 (100) 0.92 6 0.11
Diagnosis
Leukemia 36 (37.9) 39 (41.1) 12 (12.6) 5 (5.3) 3 (3.2) 0 (0) 59 (62.1) 95 (100) 0.95 6 0.10 <0.001
Lymphoma 18 (51.4) 9 (25.7) 5 (14.3) 2 (5.7) 0 (0) 1 (2.9) 17 (48.6) 35 (100) 0.86 6 0.20
Brain tumor 1 (4.3) 10 (43.5) 6 (26.1) 4 (17.4) 2 (8.7) 0 (0) 22 (95.7) 23 (100) 1.83 6 0.22
Wilms’ tumor 16 (64.0) 8 (32.0) 0 (0) 1 (4.0) 0 (0) 0 (0) 9 (36.0) 25 (100) 0.44 6 0.14
NB 6 (46.2) 5 (38.5) 1 (7.7) 0 (0) 1 (7.7) 0 (0) 7 (53.8) 13 (100) 0.85 6 0.32
Othersb 20 (40.0) 13 (26.0) 13 (26.0) 2 (4.0) 2 (4.0) 0 (0) 30 (60.0) 50 (100) 1.06 6 0.15
Chemotherapy
No 7 (87.5) 1 (12.5) 0 (0) 0 (0) 0 (0) 0 (0) 1 (12.5) 8 (100) 0.13 6 0.13 <0.001
Yes 90 (38.6) 83 (35.6) 37 (15.9) 14 (6.0) 8 (3.4) 1 (0.4) 143 (61.4) 233 (100) 1.01 6 0.07
HSCT
No 90 (45.2) 68 (34.2) 26 (13.1) 9 (4.5) 5 (2.5) 1 (0.5) 109 (54.8) 199 (100) 0.86 6 0.07 <0.001
Yes 7 (16.7) 16 (38.1) 11 (26.2) 5 (11.9) 3 (7.1) 0 (0) 35 (83.3) 42 (100) 1.55 6 0.17
Radiotherapy
No 75 (50.7) 54 (36.5) 16 (10.8) 2 (1.4) 0 (0) 1 (0.7) 73 (49.3) 148 (100) 0.66 6 0.07 <0.001
Yes 22 (23.7) 30 (32.3) 21 (22.6) 12 (12.9) 8 (8.6) 0 (0) 71 (76.3) 93 (100) 1.50 6 0.13
Surgery
No 57 (39.3) 57 (39.3) 21 (14.5) 7 (4.8) 3 (2.1) 0 (0) 88 (60.7) 145 (100) 0.91 6 0.08 0.219
Yes 40 (41.7) 27 (28.1) 16 (16.7) 7 (7.3) 5 (5.2) 1 (1.0) 56 (58.3) 96 (100) 1.09 6 0.13
aStands for the mean number of late effects for each survivor with a specific risk factor.
bOthers are shown in Table 1.
SEM, standard error of mean; NB, neuroblastoma; HSCT, hematopoietic stem-cell transplantation.
Table 6. Multivariate analysis of the effect of risk factors on the number
and severity
Risk factor No. of late
effects
Severity of
late effects
Beta P value Beta P value
Sex 20.01 0.828 0.01 0.832
Age
Age at diagnosis 0.08 0.324 0.00 0.978
Current age 0.01 0.854 0.01 0.905
Treatment
Chemotherapy 0.16 0.008 0.16 0.008
HSCT 0.23 <0.001 0.12 0.043
Radiotherapy 0.28 <0.001 0.25 <0.001
Surgery 0.20 0.003 0.07 0.285
Diagnosis
Brain tumor 0.09 0.197 0.27 <0.001
Wilms’ tumor 20.21 0.001 20.16 0.013
All factors used in the model are presented in the table.
HSCT, hematopoietic stem-cell transplantation.
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the values reported in recent studies in the United States and
The Netherlands. The main difference in the studies is likely
due to the length of follow-up. In our study, the median time
elapsed after completion of treatment was 6.1 years, and the
median time after diagnosis was 7.8. However, all three prior
studies had a follow-up period of over 15 years from diagnosis.
The difference might also be due to the treatment intensity. The
study population in this study is one of the most recent
cohorts. Recent treatments are now focusing on reducing
toxicity while achieving comparable survival rates in order to
minimize adverse health conditions [20]. Nevertheless, the fact
that nearly 60% of survivors had late effects, even within our
short study period and even with less toxic treatments, raises
concern that the survivors require regular follow-up and early
intervention for late effects.
As for the severity of late effects, 27.5% of survivors in the
United States and 40.0% in The Netherlands suffered from
grade 3 or higher late effects. Only 10.8% of survivors had grade
3 or higher late effects in our study. The differences are likely
due to the diagnoses included and the relatively short follow-up
interval. According to other studies, brain and bone tumors, in
addition to radiotherapy, are higher risk factors for late effects
[11, 13]. In the USA study, 10.9% of patients had bone tumors
and 12.7% of cases were central nervous system (CNS) tumor
survivors. In The Netherlands study, 8.5% had bone tumors
and 7.9% had CNS tumors. In our study, the proportion of
brain tumor survivors was similar (9.5%), but there were no
bone tumor survivors. Furthermore, survivors treated with
radiotherapy (38.6%) were fewer than in other studies
(62.2% [4], 44.6% [11]).
The number of late effects in this study represents the extent
of affected body systems. The brain tumor survivors had the
highest number of late effects among the diagnoses evaluated.
Survivors with radiotherapy or HSCT had an increased number
of late effects per survivor compared with survivors who did
not undergo radiotherapy or HSCT. These findings suggest that
these factors are associated with a greater effect on body
systems compared with other factors and are consistent with
other reports [4, 11, 21, 22]. The risk factors associated with
brain tumors lost their significant association with the number
of late effects in the multivariate analysis, which controlled for
the treatment modalities (Table 6). This implies that
radiotherapy and surgery were more important risk factors
than the brain tumor itself for the extent of late effects.
Radiotherapy was a significant risk factor for the overall
prevalence and severity of late effects, consistent with the
findings of many other reports [6, 23–26]. When we evaluated
the effects of radiotherapy on individual late effects such as
growth, sexual and thyroid abnormalities, radiotherapy showed
a clear tendency of more severe late effects; however, this
tendency was not confirmed by the multivariate analysis,
perhaps due to the limited number of cases.
Figure 1. Severity of overall and specific late effects according to risk factors. HSCT, hematopoietic stem-cell transplantation; overall, overall severity of late
effects per survivor; RF, risk factor; neuro, neurologic. *Significant both in univariate and multivariate analyses. P value in univariate analysis. P value in
multivariate analysis.
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Surgery, including brain surgery and nephrectomy, was
found to be associated with an increase in the severity of
endocrine and kidney abnormalities. Brain surgery is usually
linked with brain tumors and radiotherapy; in such cases, the
risk of having endocrine abnormalities is higher. The effect of
surgery on kidney abnormalities might be due to
nephrectomies for Wilms’ tumor and neuroblastoma. These
tumors are linked with the use of kidney-toxic agents like
platinum-based drugs [27]; all these factors influence the effect
of a nephrectomy on the severity of late effects.
There have been many reports documenting endocrine,
especially thyroid, abnormalities in childhood cancer survivors
[4, 11, 22, 23, 28, 29]. Our findings were consistent with prior
reports. Endocrine late effects are common and important
problems at the LTFUC. First, they adversely affect the QoL
because of the interference with normal growth and
development and psychological adjustment [26, 30, 31].
Secondly, endocrine abnormalities are the most common late
effects. Thirdly, such problems can be appropriately managed
by timely intervention during child development [30], which
further emphasizes the important role of the LTFUC.
In contrast to other factors, Wilms’ tumor survivors had
fewer and less severe late effects than the other survivors. This
finding is consistent with previous studies [4, 12]. This might
be because Wilms’ tumor has the best prognosis among
childhood cancers; it requires less intensive therapies compared
with other tumors and survivors can live without problems
with only one kidney. Therefore, Wilms’ tumor survivors seem
to have a higher QoL to some extent compared with other
tumor survivors although childhood cancer survivors generally
have almost the same QoL as the general population [32, 33].
The evaluation of age points to a higher risk of late effects
among adolescent survivors [23]. As the survivors grow older
and enter puberty, late effects become more evident in terms of
growth and pubertal development. However, the results of this
study showed no consistent findings associated with the age at
diagnosis or the current age with regard to the late effects. This
might be due to the relatively short follow-up and the fact that
many of the survivors evaluated had not entered puberty yet.
The age issue could also be related with the absence of bone
tumor survivors in this study. Bone tumors are observed most
frequently in adolescents [34]. Bone tumor survivors have more
late effects and suffer from more severe functional impairments
[35]. Moreover, second malignancies occur more frequently
than other tumor survivors [36]. Musculoskeletal late effects
including limb abnormalities might impair growth in
adolescents, and late effects would have been more evident in
the adolescent age if bone tumor survivors had been included
in this study. Because of these reasons, prevalence and severity
of late effects and frequency of second malignancy could have
been less than in other reports.
The nonrespondents (n = 167) in this study might distort the
results of this study. Because they have higher current age, age
after completion of treatment and longer time after diagnosis,
and a much higher proportion of having brain tumors than in
respondents, the frequency and severity of late effects might
have been higher and more severe if the nonrespondents had
participated in the LTFUC.
The CIs of the OR for the existence of late effects in brain
tumor survivors or survivors with chemotherapy were wide.
These findings were due to the characteristics of the study
subjects; almost all cancer survivors (96.7%) had
chemotherapy, and almost all brain tumor survivors (95.7%)
had late effects. However, it is still evident that these two factors
increased the OR.
The limitations of this study included the small study
population size and the short follow-up duration compared
with previous studies. It is possible that the prevalence of late
effects was underestimated. This could be addressed by
continued follow-up of the enrolled survivors. Another
limitation was the absence of bone tumor survivors.
This study has some unique points. This is the first report on
late effects of childhood cancer survivors in the Asian–Pacific
region. Differences in pharmacokinetics and pharmacodynamics
according to the ethnicity cause differences in efficacy and side-
effects [37]. Sociocultural background might influence health
behaviors to seek medical care such as screening tests [38]. These
factors could be related with the incidence and severity of late
effects and the participation rate in the LTFUC. Secondly, we
evaluated the overall health status of childhood cancer survivors,
not only focusing on late effects on a single-body system.
Thirdly, all survivors were examined by oncologists and assessed
with laboratory and radiological tests.
Table 7. Multivariate analysis of the effect of risk factors on the existence
of late effects
Risk factor Existence of late effects
OR (95% CI) P value
Sex
Male 1
Female 0.9 (0.5–1.6) 0.631
Age
Age at diagnosis 1.0 (0.9–1.1) 0.893
Current age 1.0 (0.9–1.1) 0.878
Treatment
Chemotherapy
No 1
Yes 22.8 (1.5–358.3) 0.026
HSCT
No 1
Yes 3.9 (1.5–9.9) 0.004
Radiotherapy
No 1
Yes 2.2 (1.1–4.5) 0.023
Surgery
No 1
Yes 1.2 (0.5–3.1) 0.636
Diagnosis
Leukemia 1
Lymphoma 0.8 (0.3–2.0) 0.597
Brain tumor 16.6 (1.4–192.8) 0.025
Wilms’ tumor 0.3 (0.1–1.2) 0.097
Neuroblastoma 1.4 (0.2–8.4) 0.716
Others 1.2 (0.5–3.0) 0.762
All factors used in the model are presented in the table.
OR, odds ratio; CI, confidence interval; HSCT, hematopoietic stem-cell
transplantation.
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In conclusion, the results of this study showed that late
effects were common in survivors and were apparent during
a short interval of follow-up after diagnosis. The most common
late effects were associated with the endocrine system.
Endocrine abnormalities can be managed by meticulous and
well-timed hormone replacement therapy. These findings
suggest that late effects of childhood cancer survivors must be
continuously monitored after the completion of cancer
treatment, so that timely and effective treatment can be
initiated.
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